In this context, melatonin was discovered to be capable of reducing scopolamine-induced apoptosis and preventing mitochondrial damage by activating signaling from Akt/ERK/CREB and enhancing memory processes through antioxidant and anti-inflammatory properties in an AD mouse model [189]. This evidence concerns the gene AKT1 and Alzheimer disease.